Early Development Programs
ZB022
ZB022, a development candidate currently in IND-enabling studies, is a potentially best-in-class, oral, brain-penetrant, TYK2-JH2 inhibitor with the potential to treat neuroinflammatory and neurodegenerative diseases. ZB022 is allosteric inhibitor of TYK2, with potentially improved selectivity and specificity and favorable PK/PD observed in preclinical studies. TYK2 inhibition is a well-established mechanism across a range of autoimmune diseases.
ZB014
ZB014, a development candidate currently in pre-clinical studies, is a half-life extended anti-CD-19 and FcγRIIb monoclonal antibody ZB014 was developed using half-life extension technology for monoclonal antibodies, and based on preclinical study results, ZB014 has the potential to provide the clinical activity and safety profile observed with obexelimab while offering a once-monthly dosing schedule.
Our Pipeline
We are advancing two potential autoimmune disease franchise molecules, obexelimab and orelabrutinib, along with other pipeline and partnered programs for patients with autoimmune diseases. View our pipeline.
